Clinical Trial Details

USOR 18283

Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/ PD-L1 Based Immunotherapy

Purpose/Objective

Request Additional Trial Information
Full Trial Details: ClinicalTrials.gov

Condition: Urothelial Cancer
Study Type: Interventional
Phase: II
Study Start Date: 04/26/2019
Study Completion Date: 05/2020

This is an international, multi-center, open-label, phase II study in patients with metastatic urothelial cancer after failure of platinum-based regimen or anti-PD-1 /PD-L1 based immunotherapy.

At least 140 patients are anticipated to be enrolled across approximately 70 sites from North America, Europe and Asia.

 

NCT Number

NCT03547973

Principal Investigator(s)

Jun F Sun, MD

Sponsor(s)

Immunomedics, Inc.

Participant Eligibility

• Age: 18 - No Maximum
• Gender: Male, Female